secwatch.observer — SEC 8-K summary
======================================

Issuer:     Evommune, Inc. (EVMN)
CIK:        0002044725
Form:       8-K
Filed at:   2026-02-10T23:59:59+00:00
Accession:  0001193125-26-043771
Event type: other_material
Sentiment:  positive
Materiality: 0.80
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Evommune reports positive Phase 2a top-line data for EVO301 in atopic dermatitis
--------------------------------------------------------------------------------

- Primary endpoint met: 99.8% of posterior distribution exceeded 8% improvement threshold vs placebo.
- Frequentist analysis showed p<0.01 at weeks 4, 8, 12; 33% placebo-adjusted EASI reduction at week 12.
- 23% of EVO301 patients achieved vIGA-AD 0/1 at week 12 vs 0% placebo.
- EVO301 well tolerated; no related serious/severe AEs or treatment discontinuations.
- Company plans Phase 2b dose-ranging trial with subcutaneous formulation; evaluating ulcerative colitis.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/2044725/000119312526043771/0001193125-26-043771-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/2044725/000119312526043771/evmn-20260210.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-043771

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer